KRAS G12C-mutated advanced colorectal cancer | Primary Research (KOL's Insight) | Market Intelligence | Epidemiology & Market Forecast-2035

KRAS mutations are a major contributor to the development of numerous cancer types. They have an oncogenic effect due to defective GTPase activity, which triggers the activation of an uncontrolled signaling pathway downstream and the overactivation of associated effectors like RAF proteins and MAP-Kinases. KRAS mutations are present in about 45% of colorectal cancers (CRC), and they are associated with resistance to specific therapies like anti-epidermal growth factor receptor (EGFR) inhibitors. Patients with metastatic KRASG12C-mutant CRC undergo standard-of-care chemotherapy regimens more quickly than those without the mutation, which may result in a lower overall survival (OS). Finding KRAS gene mutations has become more important in the management of colorectal cancer due to its numerous prognostic and therapeutic implications.

Description

KRAS mutations are a major contributor to the development of numerous cancer types. They have an oncogenic effect due to defective GTPase activity, which triggers the activation of an uncontrolled signaling pathway downstream and the overactivation of associated effectors like RAF proteins and MAP-Kinases. KRAS mutations are present in about 45% of colorectal cancers (CRC), and they are associated with resistance to specific therapies like anti-epidermal growth factor receptor (EGFR) inhibitors. Patients with metastatic KRASG12C-mutant CRC undergo standard-of-care chemotherapy regimens more quickly than those without the mutation, which may result in a lower overall survival (OS). Finding KRAS gene mutations has become more important in the management of colorectal cancer due to its numerous prognostic and therapeutic implications.

KRAS G12C-mutated advanced colorectal cancer (Epidemiology)

KRAS mutations are present in about 45% of colorectal cancers (CRC), and they are associated with resistance to specific therapies like anti-epidermal growth factor receptor (EGFR) inhibitors. Patients with metastatic KRASG12C-mutant CRC undergo standard of care chemotherapy regimens more quickly than those without the mutation, which may result in a lower overall survival (OS).

KRAS G12C-mutated advanced colorectal cancer -Current Market Size & Forecast Trends

The market for KRAS G12C-mutated advanced colorectal cancer is expected to grow significantly, driven by the increasing prevalence of this mutation in colorectal cancer patients. The global KRAS inhibitors market, which includes treatments specifically targeting KRAS G12C mutations, is projected to exceed USD 4 billion by 2029, with significant contributions from drugs like Krazati and Lumakras, which are currently in clinical trials for various solid tumors, including colorectal cancer. With ongoing clinical trials and the development of new therapies aimed at KRAS G12C mutations, this segment is well-positioned for robust growth through 2035, as advancements in targeted therapies continue to improve treatment outcomes for patients with advanced colorectal cancer.

Finding KRAS gene mutations has become more important in the treatment of colorectal cancer due to its numerous prognostic and therapeutic implications. But until recently, when the KRASG12C inhibitors sotorasib (AMG510) and adagrasib (MRTX849) were made available, attempts to develop drugs that target KRAS mutations had been unsuccessful. It appears that not all tumor types harboring the KRASG12C mutation are responsive to monotherapy approaches, despite evidence from early phase trials and preclinical studies demonstrating the safety and potential efficacy of both drugs. Patients with colorectal cancer (CRC) in particular benefit less from treatment than patients with non-small cell lung cancer (NSCLC), which is likely a result of rapid treatment-induced resistance brought on by increased epidermal growth factor receptor (EGFR) signaling. As a result, studies of EGFR inhibitor-based combination therapy are currently being carried out. In the clinical setting, preliminary phase 1/2 data have demonstrated the safety and efficacy of sotorasib and adagrasib. While KRASG12C-mutant NSCLC appears to benefit most from treatment, patients with KRASG12C-mutant CRC are also benefiting from it. Targeted therapy with adagrasib (MRTX849) monotherapy and combination therapy with cetuximab (Erbitux) have shown promise for the treatment of patients with colorectal cancer (CRC) that have the KRAS G12C mutation. The phase 3 KRYSTAL-10 (NCT04793958) trial aims to extend the early efficacy observed with the dual blockade of KRAS G12C and EGFR in patients who experience disease progression after receiving standard first-line therapy. The mixture is safe, according to the safety data. Nausea (63%), diarrhea (56%) vomiting (53%) dermatitis acneiform (47%) fatigue (47%) and dry skin (41%) were the adverse reactions to treatment that occurred most frequently.

Report Highlights

KRAS G12C-mutated advanced colorectal cancer - Current Market Trends

KRAS G12C-mutated advanced colorectal cancer - Current & Forecasted Cases across the G8 Countries

KRAS G12C-mutated advanced colorectal cancer - Market Opportunities and Sales Potential for Agents

KRAS G12C-mutated advanced colorectal cancer - Patient-based Market Forecast to 2035

KRAS G12C-mutated advanced colorectal cancer - Untapped Business Opportunities

KRAS G12C-mutated advanced colorectal cancer - Product Positioning Vis-a-vis Competitors' Products

KRAS G12C-mutated advanced colorectal cancer - KOLs Insight